Clinical Trial

The CARDIO-TTRansform Scintigraphy Sub-study

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 28, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-04; most recent amendment 2025-11-25.
Trial Details
NCT Number NCT06073587
Lead Sponsor Ionis Pharmaceuticals, Inc.
Collaborators: AstraZeneca
Conditions Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Enrollment 150 participants
Start Date 2023-04-04
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-11-28